RxDoctor Payments DataLook up a doctor →

Gina Koons

Nurse Practitioner · Harrisburg, PANPI 1013493105

Payments from drug & device makers

$10,232in general payments, 2019–2025

Across 603 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$902
  • Boehringer Ingelheim$879
  • AstraZeneca$659
  • Amgen$590
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$10,207100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,232 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,473
Medicare patients
287
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$52,083
FarxigaDapagliflozin Propanediol30$41,510
JardianceEmpagliflozin34$41,088
OzempicSemaglutide16$15,187
JanuviaSitagliptin Phosphate15$7,540
Atorvastatin Calcium105$1,677
Rosuvastatin Calcium56$1,485
SynthroidLevothyroxine Sodium24$1,331
Lisinopril104$925
Albuterol Sulfate HfaAlbuterol Sulfate38$851
Amlodipine Besylate87$789
Potassium Chloride31$764
FenofibrateFenofibrate Nanocrystallized20$729
Metoprolol Succinate38$709
Losartan Potassium68$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$902$52,08343 claims
AstraZenecaFarxiga$659$41,51030 claims
Boehringer IngelheimJardiance$879$41,08834 claims
Novo NordiskOzempic$1,169$15,18716 claims
MerckJanuvia$119$7,54015 claims
AbbVieSynthroid$1,679$1,33124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →